Glixogen Therapeutics

Company Overview

Snapshot

Founded in October 2018 by Dr. Yair Fisher and Prof. James Salzer, Glixogen Therapeutics operates with 1–10 employees. The company has secured funding across one disclosed round from one investor. In January 2019, FutuRx launched Glixogen Therapeutics to develop novel therapies for multiple sclerosis and other demyelinating disorders.

Business overview

Glixogen Therapeutics is a biopharmaceutical company focused on developing treatments to enhance remyelination in neurodegenerative disorders, specifically those driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS). The company's core technology involves selective small molecule inhibitors of the transcription factor Gli1, a novel target aimed at facilitating neuronal remyelination to modify disease outcomes. Glixogen Therapeutics operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Drugs Discovery & Development.

Strategic signal

In January 2019, FutuRx launched Glixogen Therapeutics, signaling a strategic investment in the development of novel therapies for multiple sclerosis and other demyelinating disorders. This launch highlights the potential of Glixogen's approach to neuronal remyelination and indicates early-stage validation from an incubator in the biopharmaceutical space, suggesting a focus on addressing significant unmet medical needs.

Company Intelligence Q&A

What is Glixogen Therapeutics' primary focus?

Glixogen Therapeutics is a biopharmaceutical company dedicated to developing treatments that enhance remyelination in neurodegenerative disorders, particularly those involving myelin sheath damage like multiple sclerosis (MS).

When was Glixogen Therapeutics founded?

Glixogen Therapeutics was founded in October 2018 by Dr. Yair Fisher and Prof. James Salzer.

What is the company's core technology?

Glixogen Therapeutics has discovered selective small molecule inhibitors of the transcription factor Gli1, a novel target designed to facilitate neuronal remyelination.

Which entity launched Glixogen Therapeutics?

In January 2019, FutuRx launched Glixogen Therapeutics to develop novel therapies for multiple sclerosis and other demyelinating disorders.

What is the current status of Glixogen Therapeutics?

Glixogen Therapeutics is currently Non Active, having ceased to operate in December 2024.